70 related articles for article (PubMed ID: 21748826)
1. Risk of venous thromboembolism after total hip and knee replacement in older adults with comorbidity and co-occurring comorbidities in the Nationwide Inpatient Sample (2003-2006).
Kapoor A; Labonte AJ; Winter MR; Segal JB; Silliman RA; Katz JN; Losina E; Berlowitz D
BMC Geriatr; 2010 Sep; 10():63. PubMed ID: 20846450
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of venous thromboembolism pharmacological prophylaxis in total hip and knee replacement: a systematic review.
Kapoor A; Chuang W; Radhakrishnan N; Smith KJ; Berlowitz D; Segal JB; Katz JN; Losina E
Pharmacoeconomics; 2010; 28(7):521-38. PubMed ID: 20550220
[TBL] [Abstract][Full Text] [Related]
3. Current Evidence and Expert Opinion on Thromboprophylaxis After Total Knee and Hip Replacement.
Mody BS; Wadhwa M; Roy R; Echila S
Cureus; 2023 Dec; 15(12):e51089. PubMed ID: 38274925
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism (VTE) developing after ankle sprain. Comparison with VTE after knee arthroplasty.
Gutiérrez-Guisado J; Calvo-Sotelo AE; Hernández-Blasco L; Fidalgo Á; Gómez-Cuervo C; López-Ruiz A; Aibar J; Verhamme P; Meireles J; Monreal M
Thromb Res; 2024 May; 237():94-99. PubMed ID: 38574519
[TBL] [Abstract][Full Text] [Related]
5. Non-compliance with clinical guidelines increases the risk of complications after primary total hip and knee joint replacement surgery.
Badge HM; Churches T; Naylor JM; Xuan W; Armstrong E; Gray L; Fletcher J; Gosbell I; Lin C; Harris IA
PLoS One; 2021; 16(11):e0260146. PubMed ID: 34793555
[TBL] [Abstract][Full Text] [Related]
6. Aspirin thromboprophylaxis in joint replacement surgery.
Sharda AV; Fatovic K; Bauer KA
Res Pract Thromb Haemost; 2022 Jan; 6(1):e12649. PubMed ID: 35106432
[TBL] [Abstract][Full Text] [Related]
7. NYU Clinical Practice Guidelines for VTE ProphylaxisHip and Knee Arthroplasty.
Arshi A; Rozell JC; Aggarwal VK; Schwarzkopf R
Bull Hosp Jt Dis (2013); 2024 Jun; 82(2):103-105. PubMed ID: 38739656
[No Abstract] [Full Text] [Related]
8. Bleeding risk from anticoagulant thromboprophylaxis in patients with multiple myeloma: a MarketScan analysis.
Adrianzen-Herrera D; Giorgio K; Walker RF; Sparks AD; Gergi M; Zakai NA; Lutsey PL
Res Pract Thromb Haemost; 2024 May; 8(4):102418. PubMed ID: 38798793
[TBL] [Abstract][Full Text] [Related]
9. Simplifying thromboprophylaxis could improve outcomes in orthopaedic surgery.
Friedman RJ
Thrombosis; 2010; 2010():108049. PubMed ID: 22084657
[TBL] [Abstract][Full Text] [Related]
10. The effect of new oral anticoagulants and extended thromboprophylaxis policy on hip and knee arthroplasty outcomes: observational study.
Bottle A; Oragui E; Pinder E; Aylin P; Loeffler M
Arthroplast Today; 2015 Jun; 1(2):45-50. PubMed ID: 28326369
[TBL] [Abstract][Full Text] [Related]
11. Urinary Prothrombin Fragment 1+2 in relation to Development of Non-Symptomatic and Symptomatic Venous Thromboembolic Events following Total Knee Replacement.
Borris LC; Breindahl M; Lassen MR; Pap AF
Thrombosis; 2011; 2011():150750. PubMed ID: 22084662
[TBL] [Abstract][Full Text] [Related]
12. Model-based exposure-response analysis of apixaban to quantify bleeding risk in special populations of subjects undergoing orthopedic surgery.
Leil TA; Frost C; Wang X; Pfister M; LaCreta F
CPT Pharmacometrics Syst Pharmacol; 2014 Sep; 3(9):e136. PubMed ID: 25229619
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism prophylaxis in patients undergoing knee replacements: comparison of real-world outcomes.
Hasan SS; Sunter W; Ahmed N; Dawoud D; Zaidi STR
Int J Clin Pharm; 2021 Jun; 43(3):621-628. PubMed ID: 33070296
[TBL] [Abstract][Full Text] [Related]
14. Use of rivaroxaban in Germany: a database drug utilization study of a drug started in hospital.
Jobski K; Enders D; Amann U; Suzart K; Wallander MA; Schink T; Garbe E
Eur J Clin Pharmacol; 2014 Aug; 70(8):975-81. PubMed ID: 24858823
[TBL] [Abstract][Full Text] [Related]
15. Analysis of disease patterns and cost of treatments for prevention of deep venous thrombosis after total knee or hip replacement: results from the Practice Analysis of THromboprophylaxis after Orthopaedic Surgery (PATHOS) study.
Degli Esposti L; Didoni G; Simon T; Buda S; Sangiorgi D; Degli Esposti E
Clinicoecon Outcomes Res; 2013; 5():1-7. PubMed ID: 23300348
[TBL] [Abstract][Full Text] [Related]
16. Venous thromboembolism prophylaxis after total knee or hip replacement: treatment pattern and outcomes.
Penning-van Beest FJ; Overbeek JA; Meijer WM; Woodruff K; Jackson J; van der Vis H; van der Linden P; Herings RM
Pharmacoepidemiol Drug Saf; 2011 Sep; 20(9):972-8. PubMed ID: 21748826
[TBL] [Abstract][Full Text] [Related]
17. Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.
Vekeman F; LaMori JC; Laliberté F; Nutescu E; Duh MS; Bookhart BK; Schein J; Dea K; Olson WH; Lefebvre P
J Med Econ; 2011; 14(3):324-34. PubMed ID: 21506632
[TBL] [Abstract][Full Text] [Related]
18. Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.
Selby R; Borah BJ; McDonald HP; Henk HJ; Crowther M; Wells PS
Thromb Res; 2012 Aug; 130(2):166-72. PubMed ID: 22365491
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism prevention with fondaparinux 1.5 mg in renally impaired patients undergoing major orthopaedic surgery. A real-world, prospective, multicentre, cohort study.
Mismetti P; Samama CM; Rosencher N; Vielpeau C; Nguyen P; Deygas B; Presles E; Laporte S;
Thromb Haemost; 2012 Jun; 107(6):1151-60. PubMed ID: 22476471
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
